158 related articles for article (PubMed ID: 24060416)
1. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
Alexander VM; Gordon AN; Howard DH; Khanna N
Int J Gynecol Cancer; 2017 Sep; 27(7):1333-1342. PubMed ID: 28692633
[TBL] [Abstract][Full Text] [Related]
3. The cost of surveillance following treatment of ovarian cancer.
Rustin GJ
Gynecol Oncol; 2013 Dec; 131(3):501-2. PubMed ID: 24267818
[No Abstract] [Full Text] [Related]
4. The role of regular physical examination in the detection of ovarian cancer recurrence.
Chan KK; Tam KF; Tse KY; Ngan HY
Gynecol Oncol; 2008 Aug; 110(2):158-61. PubMed ID: 18544459
[TBL] [Abstract][Full Text] [Related]
5. Post treatment surveillance of type II endometrial cancer patients.
Zakhour M; Li AJ; Walsh CS; Cass I; Karlan BY; Rimel BJ
Gynecol Oncol; 2013 Dec; 131(3):609-12. PubMed ID: 24051222
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; Viganò R; Messa C; Fazio F
Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
[TBL] [Abstract][Full Text] [Related]
7. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
Salani R; Backes FJ; Fung MF; Holschneider CH; Parker LP; Bristow RE; Goff BA
Am J Obstet Gynecol; 2011 Jun; 204(6):466-78. PubMed ID: 21752752
[TBL] [Abstract][Full Text] [Related]
8. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study.
Low RN; Saleh F; Song SY; Shiftan TA; Barone RM; Lacey CG; Goldfarb PM
Radiology; 1999 May; 211(2):519-28. PubMed ID: 10228537
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
[TBL] [Abstract][Full Text] [Related]
10. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
11. Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
Dottino JA; Cliby WA; Myers ER; Bristow RE; Havrilesky LJ
Gynecol Oncol; 2015 Sep; 138(3):694-9. PubMed ID: 26072441
[TBL] [Abstract][Full Text] [Related]
12. Patterns and utility of routine surveillance in high grade endometrial cancer.
Hunn J; Tenney ME; Tergas AI; Bishop EA; Moore K; Watkin W; Kirschner C; Hurteau J; Rodriguez GC; Lengyel E; Lee NK; Yamada SD
Gynecol Oncol; 2015 Jun; 137(3):485-9. PubMed ID: 25838164
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.
Tergas AI; Havrilesky LJ; Fader AN; Guntupalli SR; Huh WK; Massad LS; Rimel BJ
Gynecol Oncol; 2013 Sep; 130(3):421-5. PubMed ID: 23747836
[TBL] [Abstract][Full Text] [Related]
14. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer.
Titu LV; Nicholson AA; Hartley JE; Breen DJ; Monson JR
Ann Surg; 2006 Mar; 243(3):348-52. PubMed ID: 16495699
[TBL] [Abstract][Full Text] [Related]
15. Posttherapy surveillance of women with cervical cancer: an outcomes analysis.
Bodurka-Bevers D; Morris M; Eifel PJ; Levenback C; Bevers MW; Lucas KR; Wharton JT
Gynecol Oncol; 2000 Aug; 78(2):187-93. PubMed ID: 10926801
[TBL] [Abstract][Full Text] [Related]
16. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
[TBL] [Abstract][Full Text] [Related]
17. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
Low RN; Duggan B; Barone RM; Saleh F; Song SY
Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
[TBL] [Abstract][Full Text] [Related]
18. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
20. How to follow-up patients with epithelial ovarian cancer.
Miller RE; Rustin GJ
Curr Opin Oncol; 2010 Sep; 22(5):498-502. PubMed ID: 20498597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
